New Market Study, "Market And Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin Fails To Top Any Individual Market In 2011", Has Been Published

Fast Market Research recommends "Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011" from Datamonitor, now available

by Bill Thompson

(WireNews+Co) - Boston, MA - 22 October 2012

The high level of commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers. Treatment of cancer has shifted toward a more focused attack on the disease with targeted therapies. However, austerity packages imposed could see slower commercial growth and larger generic erosion of key brands.

Scope
- Analysis of the top 20 oncology therapy brands in the seven major markets
- In depth analysis of the factors influencing the top 20 oncology brands in individual countries of the seven major markets
- Sales forecasts for the top 20 cancer therapy brands from 2011 to 2021
- Brand dynamics and assessment of the top 5 cancer brands in the seven major markets

View Full Report Details and Table of Contents (http://www.fastmr.com/prod/464845_market_and_product_forecasts_top_20_oncology.aspx) (http://www.fastmr.com/prod/464845_market_and_product_forecasts_top_20_oncology.aspx)

Highlights

The total sales of the top 20 cancer therapy brands in the seven major markets was $37.2bn in 2011, with targeted therapies representing 74% of those sales. However, the oncology market is fragmenting as developers focus on niche subsets of patients with specific genetic mutations, making it harder for drugs to reach blockbuster status.

Targeted therapies dominated the market, and will increase their share of the top 20 as patent expiries continue to impact sales of other drug classes. Generic erosion of multiple key brands in the cytotoxic class will be the key driver in decreasing its share of the top 20 branded sales from 17% in 2011 to 10% in 2021.

Avastin did not achieve the top position in any of the individual markets, the US, Japan, or 5EU, due to a combination of US indication removal, cost-conservative EU markets, strong antihormonal sales in Japan, and tough Swiss Franc exchange rates.

Reasons to Get this Report
- Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets in 2011 and 2021.
- Acquire an account of top-selling cancer brand dynamics and the events that drive and limit their market growth.
- The report is accompanied by a PowerPoint presentation and Excel deliverable showing full top 20 forecasts for the US, Japan and 5EU.

Fast Market Research (http://www.fastmr.com) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.